

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Pomalidomide with dexamethasone for treating
relapsed and refractory multiple myeloma after
lenalidomide and bortezomib (review of TA338)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No equality issues were raised.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No equality issues were raised or discussed by the committee.

- | |
|--|
| 4. Do the recommendations make it more difficult in practice for a |
|--|

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after lenalidomide and bortezomib (review of TA338)

Issue date: November 2016

specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
N/A

Approved by Programme Director (name): Frances Sutcliffe.....

Date: 26/10/2016